At a glance

At a glance

Key figures (IFRS)

 

 

 

 

(thousands of €, if not stated otherwise)

31/12/2017

31/12/2016

31/12/2015

(1)

The operational cash burn (or operational cash flow if this performance measure is positive) is equal to the sum of the net cash flows generated / used (–) in operating activities and the net cash flows generated / used (–) in investing activities minus (i) the proceeds or cash used, if any, in acquisitions or disposals of businesses; and (ii) the movement in restricted cash, if any. This alternative performance measure is in our view an important metric for a biotech company in the development stage. For 2016, the operational cash flow generated represented €231.9 million, which was significantly impacted by the upfront payment from Gilead of €275.6 million.

Income Statement

 

 

 

Revenues

127,087

129,519

39,563

Other income

28,830

22,093

21,017

R&D expenditure

(218,502)

(139,573)

(129,714)

S, G&A expenses

(27,218)

(23,530)

(20,308)

Operating expenses

(245,720)

(163,103)

(150,023)

Operating loss

(89,802)

(11,491)

(89,444)

Net financial results

(25,705)

65,737

(30,184)

Taxes

(198)

(235)

1,218

Net income / loss (–)

(115,704)

54,012

(118,410)

 

 

 

 

Balance sheet

 

 

 

Cash, cash equivalents and restricted cash

1,152,369

980,909

348,216

R&D incentives receivables

75,783

64,342

58,545

Assets

1,286,274

1,083,338

442,514

Shareholders' equity

1,011,983

758,701

364,999

Deferred income

219,892

285,612

39,806

Other liabilities

54,399

39,025

37,709

 

 

 

 

Cash flow

 

 

 

Operational cash burn (–) / operational cash flow(1)

(154,089)

231,881

(121,145)

Cash flow from financing activities

353,357

395,996

271,370

Effect of currency exchange rate fluctuation on cash and cash equivalents

(27,808)

4,816

118

Increase in cash, cash equivalent and restricted cash

171,460

632,693

150,343

Cash, cash equivalents and restricted cash on 31 December

1,152,369

980,909

348,216

 

 

 

 

Financial ratios

 

 

 

Number of shares issued on 31 December

50,936,778

46,256,078

39,076,342

Basic income / loss (–) per share (in €)

(2.34)

1.18

(3.32)

Diluted income / loss (–) per share (in €)

(2.34)

1.14

(3.32)

Share price on 31 December (in €)

78.98

60.94

56.76

Total group employees on 31 December (number)

600

508

435

Employees per site

Employees per site (graphic)

Number of employees Galapagos group

Number of R&D employees (bar chart)